Biogened Statistics

Total Valuation

Biogened has a market cap or net worth of PLN 66.32 million. The enterprise value is 85.57 million.

Market Cap	66.32M
Enterprise Value	85.57M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	Sep 11, 2025

Share Statistics

Biogened has 2.46 million shares outstanding.

Current Share Class	2.46M
Shares Outstanding	2.46M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	1.17%
Float	144,714

Valuation Ratios

The trailing PE ratio is 13.88.

PE Ratio	13.88
Forward PE	n/a
PS Ratio	0.58
PB Ratio	1.57
P/TBV Ratio	1.58
P/FCF Ratio	16.33
P/OCF Ratio	8.73
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.14, with an EV/FCF ratio of 21.07.

EV / Earnings	17.90
EV / Sales	0.75
EV / EBITDA	6.14
EV / EBIT	8.85
EV / FCF	21.07

Financial Position

The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.57.

Current Ratio	2.10
Quick Ratio	1.18
Debt / Equity	0.57
Debt / EBITDA	1.73
Debt / FCF	5.93
Interest Coverage	3.89

Financial Efficiency

Return on equity (ROE) is 11.91% and return on invested capital (ROIC) is 9.52%.

Return on Equity (ROE)	11.91%
Return on Assets (ROA)	6.86%
Return on Invested Capital (ROIC)	9.52%
Return on Capital Employed (ROCE)	15.23%
Revenue Per Employee	512,091
Profits Per Employee	21,431
Employee Count	209
Asset Turnover	1.30
Inventory Turnover	1.62

Taxes

In the past 12 months, Biogened has paid 2.35 million in taxes.

Income Tax	2.35M
Effective Tax Rate	33.00%

Stock Price Statistics

The stock price has increased by +34.34% in the last 52 weeks. The beta is 0.37, so Biogened's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	+34.34%
50-Day Moving Average	28.52
200-Day Moving Average	24.25
Relative Strength Index (RSI)	43.19
Average Volume (20 Days)	33

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Biogened had revenue of PLN 114.20 million and earned 4.78 million in profits. Earnings per share was 1.95.

Revenue	114.20M
Gross Profit	79.26M
Operating Income	9.67M
Pretax Income	7.13M
Net Income	4.78M
EBITDA	13.94M
EBIT	9.67M
Earnings Per Share (EPS)	1.95

Full Income Statement

Balance Sheet

The company has 4.85 million in cash and 24.09 million in debt, giving a net cash position of -19.25 million or -7.84 per share.

Cash & Cash Equivalents	4.85M
Total Debt	24.09M
Net Cash	-19.25M
Net Cash Per Share	-7.84
Equity (Book Value)	42.36M
Book Value Per Share	17.25
Working Capital	30.50M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.60 million and capital expenditures -3.54 million, giving a free cash flow of 4.06 million.

Operating Cash Flow	7.60M
Capital Expenditures	-3.54M
Free Cash Flow	4.06M
FCF Per Share	1.65

Full Cash Flow Statement

Margins

Gross margin is 69.41%, with operating and profit margins of 8.47% and 4.19%.

Gross Margin	69.41%
Operating Margin	8.47%
Pretax Margin	6.25%
Profit Margin	4.19%
EBITDA Margin	12.20%
EBIT Margin	8.47%
FCF Margin	3.56%

Dividends & Yields

This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 1.85%.

Dividend Per Share	0.50
Dividend Yield	1.85%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	3
Payout Ratio	25.70%
Buyback Yield	n/a
Shareholder Yield	1.85%
Earnings Yield	7.21%
FCF Yield	6.12%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogened has an Altman Z-Score of 2.82 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.82
Piotroski F-Score	6